Heartseed (219A) · InitiativeRestated
Safety management through purification and immunosuppression
First written in FY2024. 1 of 2 entries say "Restated". Latest entry: FY2025.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Safety Management in Regenerative Medicine Through Purification and ImmunosuppressionA theme 3 companies write about · 1 as a headwind · 2 as a tailwind
1 other company's latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2025RestatedAnnual report
「Immediately after administration of the myocardial spheres, patients begin taking a total of 3 immunosuppressants at doses below those used for heart transplantation. The number and dosage are gradually reduced, and after 26 weeks, only 1 drug is continued at a very low dose.」
The Company continues its safety management protocol combining purification with the stepwise reduction of immunosuppressants. - FY2024First statedAnnual report
「In the LAPiS trial for HS-001, the protocol begins with 3 immunosuppressants at doses lower than those used for heart transplantation, then progressively reduces both the dosages and the number of drugs as the trial advances. After 6 months, only 1 drug remains, and its dosage can be substantially reduced at the physician's discretion.」
The Company seeks to reduce the risks of tumor formation, immune rejection and arrhythmia through purification, nonclinical studies and the stepwise reduction of immunosuppressants.